

1 **Early Treatment of Favipiravir in COVID-19 Patients Without Pneumonia: A Multicentre,**  
2 **Open-Labelled, Randomized Control Study**

3 Rujipas Sirijatuphat<sup>a</sup>, Weerawat Manosuthi<sup>b</sup>, Suvimol Niyomnaitam<sup>c,d</sup>, Andrew Owen<sup>e</sup>,  
4 Katherine K. Copeland<sup>f</sup>, Lantharita Charoenpong<sup>b</sup>, Manoch Rattanasompattikul<sup>g</sup>, Surakameth  
5 Mahasirimongkol<sup>h</sup>, Kulkanya Chokephaibulkit<sup>d,i,\*</sup>

6  
7 *<sup>a</sup>Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University,*  
8 *Thailand; <sup>b</sup>Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi,*  
9 *Thailand; <sup>c</sup>Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol*  
10 *University, Thailand; <sup>d</sup>Siriraj Institute of Clinical Research (SICRES), Mahidol University,*  
11 *Thailand; <sup>e</sup>Institute of Systems, Molecular and Integrative Biology, University of Liverpool,*  
12 *United Kingdom; <sup>f</sup>Mahidol University International College, Salaya, Nakhon Pathom, Thailand;*  
13 *<sup>g</sup>Medical Department, Golden Jubilee Medical Centre, Faculty of Medicine Siriraj Hospital,*  
14 *Mahidol University, Thailand; <sup>h</sup>Division of Genomic Medicine and Innovation Support,*  
15 *Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand; <sup>i</sup>Department*  
16 *of Paediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand*

17  
18 **\*Corresponding author:** Kulkanya Chokephaibulkit, MD,

19 *2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand*

20 *Tel: (+66) 2-4141899; Fax: (+66) 2-4128243,*

21 *E-mail: [kulkanya.cho@mahidol.ac.th](mailto:kulkanya.cho@mahidol.ac.th).*

## 22 Abstract

23 We investigated Favipiravir (FPV) efficacy in mild cases of COVID-19 without pneumonia and  
24 its effects towards viral clearance, clinical condition, and risk of COVID-19 pneumonia  
25 development. PCR-confirmed SARS-CoV-2-infected patients without pneumonia were enrolled  
26 (2:1) within 10 days of symptomatic onset into FPV and control arms. The former received 1800  
27 mg FPV twice-daily (BID) on Day 1 and 800 mg BID 5-14 days thereafter until negative viral  
28 detection, while the latter received supportive care only. The primary endpoint was time to clinical  
29 improvement, which was defined by a reduced National Early Warning Score (NEWS) or score of  
30  $\leq 1$ . 62 patients (41 female) comprised the FPV arm (median age: 32 years, median BMI: 22 kg/m<sup>2</sup>)  
31 and 31 patients (19 female) comprised the control arm (median age: 28 years, median BMI: 22  
32 kg/m<sup>2</sup>). The median time to sustained clinical improvement by NEWS was 2 vs 14 days for FPV  
33 and control arms respectively (adjusted hazard ratio (aHR) of 2.77, 95% CI 1.57-4.88,  $P < 0.001$ ).  
34 The FPV arm also had significantly higher likelihoods of clinical improvement within 14 days  
35 after enrolment by NEWS (79% vs 32% respectively,  $P < 0.001$ ), particularly female patients (aOR  
36 6.35, 95% CI 1.49-27.07,  $P < 0.001$ ). 8 (12.9%) and 7 (22.6%) patients in FPV and control arms  
37 developed mild pneumonia at a median (range) 6.5 (1-13) and 7 (1-13) days after treatment,  
38 respectively ( $P = 0.316$ ); all recovered well without complications. We can conclude that early  
39 treatment of FPV in symptomatic COVID-19 patients without pneumonia was associated with  
40 faster clinical improvement.

41

42 **Key words:** COVID-19; Favipiravir; Thailand; Antiviral; RdRp Inhibitor

## 43 **Introduction**

44 Across 226 countries and territories, over 517 million cases and 6.2 million deaths have been  
45 recorded for SARS-CoV-2 as of May 13<sup>th</sup>, 2022 [1]. Its viral spread relies on angiotensin  
46 converting enzyme 2 (ACE-2) receptor binding, RNA-dependent RNA polymerase (RdRp), as  
47 well as other host and viral proteins important for successful transmission and replication [2,3]. In  
48 80-90% of these cases, the infection is self-limiting and relatively mild or moderate, bearing a  
49 presentation and organ tropism similar to Influenza [2-5]. However, some patients experience life-  
50 threatening complications and post-acute COVID-19 syndrome [2,6-10]. Several interventions  
51 have emerged in the past 2 years for treating COVID-19, but there remains a critical need for  
52 widely available medicines. Accordingly, multiple existing antivirals are being investigated for  
53 their suitability to be repurposed and studied as possible treatment options [2,3,11-14].

54  
55 Easily utilizable antivirals capable of inhibiting SARS-CoV-2 replication mechanisms are greatly  
56 desired – particularly for treating mild-to-moderate cases, which comprise a majority of reported  
57 illnesses. Such treatments could help prevent downstream complications and diminish  
58 transmission. Remdesivir (RDV) was one such early-implemented, USFDA-approved antiviral  
59 [15]. It had been used in multiple clinical trials to treat moderate or severe cases of COVID-19  
60 with pneumonia or under oxygen supplementation [11,16-18], and in non-hospitalized patients  
61 [19]. Its limited clinical application, high cost (\$390 per 100 mg vial), and intravenous mode of  
62 administration rendered RDV less applicable in resource-limited countries afflicted by a large  
63 number of COVID-19 cases [11,17]. In addition to RDV, molnupiravir (MPV) and  
64 nirmatrelvir/ritonavir have also recently received conditional approvals in some territories for use  
65 in outpatients. Further to publication of phase II/III MOVE-OUT trial for MPV [20], several

66 commentators have however queried the available data [21,22] and larger studies are ongoing to  
67 clarify the utility in different patient groups.

68

69 Favipiravir (FPV) is another promising antiviral drug. It is a broad-spectrum antiviral previously  
70 used to treat numerous diseases, including re-emerging or novel cases of Influenza [23,24], and  
71 has since been repurposed to treat SARS-CoV-2 [3,5,25]. FPV was shown to inhibit SARS-CoV-  
72 2 *in-vitro* in infected Vero E6 cells [11,12,26] and appeared to improve clinical outcomes, control  
73 viral progression, and promote viral clearance in numerous clinical studies [3,4,6,8,9,27,28];  
74 however, the clinical benefit was not clearly demonstrated in some studies [29-33]. More than  
75 4000 well-characterized patient safety profiles illustrated that effective FPV drug concentrations  
76 remained within safe therapeutic dosages [6,26,34]. This, coupled with it being easily, orally  
77 administrable (200 mg/tablet of AVIGAN) [35] and having a relatively low cost (\$0.5-1.0 per pill)  
78 compared to RDV, MPV, and nirmatrelvir/ritonavir render it a worthy candidate for further  
79 evaluation [17,36]. Some countries have already approved, even commercialized, its use for  
80 treating mild or moderate COVID-19 [6,31,37-41].

81

82 RDV, MPV and FPV are all nucleoside-based drugs, which target the viral RdRp. However, unlike  
83 RDV that exerts its antiviral action by chain termination, MPV and FPV elicit their effects via a  
84 mechanism termed lethal mutagenesis [42,43] In this mechanism, the active metabolite is  
85 incorporated into the genomic or sub-genomic RNA, rather than endogenous nucleosides while  
86 copying the RNA template genome. The resultant drug-containing RNAs are then themselves used  
87 as a template for production of subsequent RNAs causing mistakes to be made in copying, to an  
88 extent that mutated genomes are not thought to form functional viruses.

89 Despite limited evidence of its benefits, Thailand has deployed FPV to treat COVID-19 since the  
90 start of the pandemic. While initial studies showed promise, particularly upon early treatment (<4  
91 days after infection) [44,45], more clinical trials are required to further support and characterize  
92 FPV's clinical applications [46,47]. In this study, we sought to investigate the efficacy of early  
93 FPV treatment towards clinical benefit, viral clearance, and risk of developing COVID-19  
94 pneumonia in mild cases of COVID-19 without pneumonia.

95

## 96 **Methods**

97 This multicentre, open-labelled, randomized prospective cohort took place from December 2020  
98 to July 2021 at three medical centres in Bangkok: Bamrasnaradura Infectious Diseases Institute,  
99 Golden Jubilee Medical Centre, and Faculty of Medicine Siriraj Hospital. Eligible subjects were  
100 PCR-confirmed SARS-CoV-2 infected individuals, 18 years or older, with mild-to-moderate  
101 symptoms and without pneumonia. Subjects with pneumonia, in critical condition, that had a  
102 symptomatic onset >10 days, were suspected or confirmed to have concurrent or concomitant  
103 infections, that received immunosuppressive treatment, received or were on medication with  
104 possible SARS-CoV-2 antiviral activity (*e.g.*, interferon alpha, lopinavir, chloroquine,  
105 hydroxychloroquine, ivermectin, favipiravir, and remdesivir), pregnant or possibly pregnant, or  
106 lactating were excluded from the study. After providing written informed consent, participants  
107 were randomized 2:1 into FPV and control arms. On top of supportive care, the FPV arm received  
108 oral administrations of FPV (Fujifilm Toyama Chemical co., Ltd.; 200 mg per tablet) as a dosing  
109 regimen of 1800 mg twice-daily (BID) for 1 day (9 tablets per dose) and 800 mg BID (4 tablets  
110 per dose) thereafter until clinical improvement or saliva RT-PCR became negative (min-max of 5-  
111 14 days). The control arm received only symptomatic therapy. This study was approved by each

112 study site's institutional ethic committee and was conducted in accordance with the Declaration of  
113 Helsinki, Belmont Report, and International Council on Harmonisation's Good Clinical Practice.  
114 The study was registered in [thaiclinicaltrials.org](http://thaiclinicaltrials.org) (TCTR20200514001) [48].

115  
116 Patients were hospitalized for at least 7 days. Clinical findings, clinical symptoms, and oxygen  
117 saturation (SpO<sub>2</sub>) were reported daily, and vital signs were recorded twice-daily during  
118 hospitalization. Laboratory tests for monitoring safety (included haematology and chemistry) were  
119 performed on days 1, 4, 7, 10, 15, 22, and 28; saliva SARS-CoV-2 RNA (viral load) and chest  
120 imaging were performed every 3 days from days 1-28; and 12-lead ECG values were recorded on  
121 days 1, 14, and 28.

122  
123 Efficacy evaluation included: the duration and resolution of pyrexia (body temperature  $\leq 37.4$  °C);  
124 clinical severity assessed by National Early Warning Score (NEWS) that based on individual  
125 physiological parameters (respiration rate, SpO<sub>2</sub>, any supplemental oxygen, temperature, systolic  
126 blood pressure, heart rate, and level of consciousness) [49]; absence of new chest imaging findings;  
127 and negative SARS-CoV-2 RT-PCR result from saliva specimen.

### 128 129 *Statistical Analysis*

130 Clinical improvement was defined as reduced NEWS from baseline or score of  $\leq 1$ . Sustained  
131 clinical improvement was defined as an improvement for 7 days or until discharge. All endpoints  
132 were monitored from the start of FPV administration to 28 days.

133

134 Descriptive analyses were conducted to provide general information about the patients in each  
135 arm, where continuous variables were reported as mean, standard deviation (SD), median,  
136 interquartile range (IQR), and categorical variables were reported as absolute (numbers) and  
137 relative (percentage) frequencies.

138

139 Log-rank tests were performed to test whether there was a difference in probability between patient  
140 arms from treatment initiation to ‘sustained improvement’ by NEWS. Primary endpoints were  
141 right-censored on Day 28, due to late sustained improvement of patients in the study. Graphs were  
142 generated using the Kaplan-Meier method, presenting survival probability as confidence intervals.  
143 Hazard ratios were derived using the regression coefficient of the Cox model – adjusted for  
144 demographic characteristics and SARS-CoV-2 viral load level as covariates. Proportional hazards  
145 (PH) assumption was checked using statistical tests and graphical diagnostics based on scaled  
146 Schoenfeld residuals.

147

148 Viral load clearance rate was determined by comparing the cumulative percent viral load level that  
149 fell below the detection limit and were compared within group using paired *t* test. Graphs were  
150 generated using the Kaplan-Meier method. Binary logistic regression was conducted to identify  
151 factors associated with sustained improvement within the first 14 days after receiving treatment.  
152 Models were checked for collinearity and homoscedasticity, and robust standard errors were used.  
153 Data was analysed using STATA, version 15.1 (STATA Corp, College Station, TX, USA), with a  
154 statistical significance of  $P < 0.05$ ). Figures were visualized using GraphPad Prism 9.0 software  
155 and R program.

156

157 **Results**

158 Of the 93 participants enrolled, 62 patients (41 female) comprised the FPV arm, with a median age  
159 of 32 years (IQR of 27-39 years), median BMI of 22 kg/m<sup>2</sup> (IQR of 19-25 kg/m<sup>2</sup>); and 31 patients  
160 (19 female) comprised the control arm, median age of 28 years (IQR of 25-35 years), median BMI  
161 of 22 kg/m<sup>2</sup> (IQR of 19-26 kg/m<sup>2</sup>) (Table 1). There was no significant difference in prevalence of  
162 underlying conditions (9.7% vs 6.5%), duration of COVID-19 symptoms before enrolment (mean  
163 1.66 vs 1.64 days; 90% and 84% were <4 days respectively), and clinical presentations observed  
164 between the two arms – with the exception being the higher prevalence of fever in the FPV arm  
165 (29% vs 10%, Table 1). SARS-CoV-2 genotypes were similarly distributed between arms, with  
166 alpha being the predominant variant.

167  
168 The median time to sustained clinical improvement by NEWS was 2 days vs 14 (range of 1-28  
169 days for both) for FPV and control arms respectively (adjusted hazard ratio (aHR) of 2.77, 95%  
170 CI 1.57-4.88,  $P < 0.001$ ) (Figure 1). Patients that received FPV also had significantly higher  
171 likelihoods of clinical improvement within 14 days after enrolment by NEWS (79% vs 32%  
172 respectively,  $P < 0.001$ ) (Figure 2). However, the proportion of patients with reported resolution of  
173 symptoms (*e.g.*, dry cough, sore throat, headache, and nasal congestion) were not significantly  
174 different between arms (see Supplementary Figure 1).

175  
176 Among subjects in the FPV arm, female patients were more likely to experience clinical  
177 improvement within 14 days compared to male patients (aOR 6.35, 95% CI 1.49-27.07,  $P < 0.001$   
178 (Table 2). Upon performing a regression analysis, FPV administration was the only independent  
179 factor associated with clinical improvement by NEWS within 14 days.

180 There was no significant difference in saliva viral load during treatment between the two arms  
181 (Figure 3A). However, saliva viral load levels were lower in the FPV arm on days 1 and 13 of  
182 treatment for participants with baseline viral loads in the lowest quartile, and on day 28 for those  
183 with baseline viral loads in the highest quartile (Figure 3 B, C). There was no significant difference  
184 in time to undetectable virus in saliva samples from FPV and control arms (median 19 vs 16 days;  
185 IQR of 10-28 days for both, aHR 0.96, 95% CI 0.58-1.58,  $P = 0.871$ , see Supplementary Figure  
186 2). There was no correlation between time to sustained clinical improvement and time to  
187 undetectable virus in saliva ( $r = 0.13$ ,  $P = 0.65$ ).

188  
189 Although the FPV arm showed significantly higher blood uric acid levels on days 4, 7, and 10 ( $P$   
190  $< 0.001$  for all time points, see Supplementary Figure 3 and Supplementary Table 1), there were  
191 no associated clinical symptoms and blood uric acid levels became normalized by day 28, with no  
192 difference between arms. Participants in the FPV arm had higher alanine aminotransferase (ALT)  
193 levels on day 10 (mean (range) of 32.0 (25.9-40.1) U/L and 26.6 (24.5-31.6) U/L for FPV and  
194 control arms respectively, where  $P = 0.0258$ ), and longer QT intervals on days 14 and 28 ( $P <$   
195  $0.001$  for both days). Although, all values were within normal limits (see Supplementary Figure 3  
196 and Supplementary Table 1). There were no differences in C-reactive protein and procalcitonin  
197 levels during treatment between arms.

198  
199 Thirty-six and 10 adverse events (AEs) were respectively reported FPV and control arms, all  
200 relatively mild and fully resolved within the 28<sup>th</sup> day of treatment. FPV-related AEs, as determined  
201 by investigator, were: hyperuricemia ( $n = 11$ ), maculopapular rashes ( $n = 3$ ), leukopenia ( $n = 1$ ),  
202 and increased SGPT ( $n = 1$ ). One of the three patients that developed a maculopapular rash

203 discontinued FPV treatment. All three cases were relatively mild, and completely resolved by the  
204 end of the study. 8 (12.9%) and 7 (22.6%) patients in FPV and control arms ( $P = 0.316$ )  
205 respectively developed mild pneumonia at a median (range) 6.5 (1-13) and 7 (1-13) days after  
206 treatment, respectively; all recovered well without complications.

207

## 208 **Discussion**

209 This prospective cohort evaluated the clinical efficacy of FPV treatment at a dosage of 1800/800  
210 BID for 5-14 days in patients with mild-to-moderate COVID-19 without pneumonia. Patients  
211 received treatment for an average 1.6 days after disease onset (90% before 4 days). Using the  
212 unbiased NEWS clinical severity assessment system, we found that patients (females in particular)  
213 treated with FPV were significantly more likely to experience clinical improvement from COVID-  
214 19 within 14 days than controls. FPV-administered patients had shorter time to sustained clinical  
215 improvement – a median 2 days compared to 14 days without FPV. There was no evident benefit  
216 on overall viral load, although patients with lower baseline viral loads had greater viral reductions  
217 on days 1 and 13 of treatment. Patients in the FPV arm were less likely to develop pneumonia,  
218 although this was not statistically significant. FPV was generally well tolerated but often  
219 associated with asymptomatic hyperuricemia.

220

221 These findings coincide with multiple reviews and meta-analyses supporting FPV's clinical  
222 efficacy after 7–14-day regimens [13,14,25,32,33,50]. The Japanese Association for Infectious  
223 Diseases reported rates of symptomatic improvement after a 14-day course of FPV in 90% of  
224 patients with mild COVID-19 [28]. Sawanpanyalert et al (2021) demonstrated that the 140 Thai  
225 patients admitted and treated with FPV within 4 days upon symptomatic onset, in conjunction to

226 other treatment modalities, had significantly lower odds of experiencing poor outcomes compared  
227 to those initiated treatment after 4 days of onset. Similarly, other studies also showed that early  
228 treatment, particularly by 4 days of onset, was associated with earlier defervescence [8,45]. These  
229 reports highlight the importance of early intervention and its clinical benefits, as observed in our  
230 study.

231  
232 Many studies also demonstrated FPV's ability to inhibit viral progression and promote viral  
233 clearance compared to other antivirals [4,13,51,52]. Doi et al (2020) emphasized that more  
234 efficient and rapid viral clearance rates and defervescence were respectively observed upon early  
235 treatment, and Ivashchenko et al (2021) discussed further how prolonged treatment regimens  
236 promoted this clearance. A recent meta-analysis revealed that FPV treatment in mild-to-moderate  
237 cases of COVID-19 was associated with higher viral clearance and shorter hospital stay, but not  
238 beneficial in severe COVID-19 cases [52]. Other studies revealed lack of benefit of FPV treatment  
239 due to insufficient evidence that FPV affects rates of mortality, mechanical ventilation, and viral  
240 clearance [31-33]. Our study with mild-to-moderate COVID-19 patients also found no significant  
241 difference in viral clearance rate, despite clear clinical improvement – except in the subgroup with  
242 low baseline viral load. However, viral clearance may not be an appropriate measure of treatment  
243 efficacy, as some patients may have recovered – or even be symptom-free – but still have  
244 detectable high viral titres [31]. Furthermore, drugs with a lethal mutagenesis mechanism of action  
245 may be more prone to the inadequacies of a viral RNA endpoint because viral RNA may  
246 theoretically be sufficiently conserved within the primer/probe target sequences so as to be  
247 detected, but mutated elsewhere to a degree that they are unable to produce infectious virus.  
248 Indeed, while an impact upon viral RNA clearance was detected in phase II for MPV (which also

249 executes lethal mutagenesis), more marked differences in infectious virus titres were observed  
250 [53].

251  
252 While demonstrating significant clinical benefit, RDV treatment in 562 non-hospitalized patients  
253 showed no efficacy on viral clearance [19]. As late-phase inflammatory responses lie behind  
254 severe COVID-19 illness, antiviral treatment may only prove beneficial towards controlling viral  
255 replication upon early administration, therefore reducing subsequent inflammatory responses. This  
256 could explain the limited clinical benefits of RDV observed in the WHO Solidarity Trial  
257 Consortium (2021) and DisCoVeRy trials [54] across patients of different clinical conditions and  
258 varied treatment initiation.

259  
260 Other studies also found FPV to be safe for short-term usage, with relatively mild or moderate AEs  
261 [52]. Some typically observed side effects included: hyperuricemia; elevated triglycerides, serum  
262 ALT, and serum uric acid; gastrointestinal discomfort; and abnormal liver function [8,9,11,13,33].  
263 No significant differences in incidence and prevalence of AEs between FPV and control arms were  
264 observed [32,33,50,52]. These events are thought to be related to elevated liver function, QT  
265 prolongation, skin rashes, and OAT1, OAT3, and URAT1 receptor inhibition [28]. The FPV  
266 regimen in our study appeared well tolerated by participants in general. A majority experienced  
267 relatively mild AEs and all fully recovered thereafter.

268  
269 Our study has some clear limitations. The first was its open label, which could lead to subjective  
270 symptomatology bias. We avoided using self-reported symptoms and used NEWS to quantify  
271 clinical response instead. We did not assess improvement of subjective symptoms (*e.g.*, cough,

272 sore throat, headache, nasal congestion), which could be affected by other factors. The second  
273 limitation was that our results cannot be directly applied to severe cases of COVID-19, as we  
274 targeted mild-to-moderate COVID-19 cases without pneumonia. Most of the participants were  
275 relatively healthy, making extrapolations to patient at risk of severe COVID-19 difficult – as found  
276 in another study [55]. The third limitation was our small sample size, which made it difficult to  
277 demonstrate the benefits of preventing disease progression. Although, we did observe a decreased  
278 prevalence of pneumonia in the FPV arm.

279  
280 To summarize, our findings support previous literature that early administration of FPV in mild  
281 COVID-19 expedites recovery, and is relatively safe for short-term usage. This is relevant to a  
282 majority of patients, who are affected by mild SARS-CoV-2. While novel antiviral agents (*e.g.*,  
283 nirmatrelvir/ritonavir and MPV) continue to emerge and substantive efforts are underway to  
284 address access for low- and middle-income countries [56,57], their current exorbitant prices,  
285 restricted accessibility in resource-limited settings, and poorly characterized pharmacokinetic and  
286 safety profiles would not render them a first choice in resource-limited settings for the time being.  
287 Publicly available information regarding the pharmacokinetics of FPV in different populations are  
288 currently extremely sparse, but will be critical to understand whether some of the differences  
289 between studies can be explained by regional differences in exposure. More data is required in this  
290 area, but current understanding does support that antiviral concentrations may be achieved within  
291 doses already administered to humans [58]. Due to its safety and comparative current cost, FPV  
292 may be a suitable treatment for mild COVID-19 without pneumonia. Further studies are required  
293 to evaluate the benefits of FPV treatment on post-acute COVID-19 syndrome and other  
294 complications.

295 **Acknowledgements**

296 This study was developed in collaboration of Faculty of Medicine Siriraj Hospital, Mahidol  
297 University and National Centre for Global Health and Medicine, Japan. The study drug  
298 (favipiravir) was supported by FUJIFILM Toyama Chemical Co., Ltd. We would like to thank all  
299 the staff in the three participating hospitals who provided support for this study.

300

301 **Funding**

302 This work was supported by the National Research Council of Thailand under grant (63-088); and  
303 the Siriraj Research and Development Fund, Faculty of Medicine Siriraj Hospital, Mahidol  
304 University under grant (IO: R016434001). AO acknowledges funding from Unitaid for project  
305 LONGEVITY, Wellcome Trust under grant (222489/Z/21/Z); EPSRC under grant  
306 (EP/R024804/1; EP/S012265/1); and NIH under grant (R01AI134091; R24 AI118397).

307

308 **Declaration of Interest Statement**

309 AO is a Director of Tandem Nano Ltd and co-inventor of patents relating to drug delivery. AO has  
310 received research funding from ViiV Healthcare, Merck and Janssen and consultancy from Gilead,  
311 ViiV and Merck not related to COVID19 or the current work. Other authors have none to declare.

312 **References**

- 313 1. Organization WH. WHO Coronavirus (COVID-19) Dashboard 2022. Available from:  
314 <https://covid19.who.int/>
- 315 2. Kutsuna S. Coronavirus disease 2019 (COVID-19): research progress and clinical practice.  
316 *Glob Health Med.* 2020 Apr 30;2(2):78-88.
- 317 3. Chen PJ, Chao CM, Lai CC. Clinical efficacy and safety of favipiravir in the treatment of  
318 COVID-19 patients. *J Infect.* 2021 May;82(5):186-230.
- 319 4. Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: An  
320 Open-Label Control Study. *Engineering (Beijing).* 2020 Oct;6(10):1192-1198.
- 321 5. Pongpirul WA, Wiboonchutikul S, Charoenpong L, et al. Clinical course and potential  
322 predictive factors for pneumonia of adult patients with Coronavirus Disease 2019 (COVID-19): A  
323 retrospective observational analysis of 193 confirmed cases in Thailand. *PLoS Negl Trop Dis.*  
324 2020 Oct;14(10):e0008806.
- 325 6. Joshi S, Parkar J, Ansari A, et al. Role of favipiravir in the treatment of COVID-19. *Int J*  
326 *Infect Dis.* 2021 Jan;102:501-508.
- 327 7. Alene M, Yismaw L, Assemie MA, et al. Magnitude of asymptomatic COVID-19 cases  
328 throughout the course of infection: A systematic review and meta-analysis. *PLoS One.*  
329 2021;16(3):e0249090.
- 330 8. Doi Y, Hibino M, Hase R, et al. A Prospective, Randomized, Open-Label Trial of Early  
331 versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. *Antimicrob Agents*  
332 *Chemother.* 2020 Nov 17;64(12).

- 333 9. Udhwadia ZF, Singh P, Barkate H, et al. Efficacy and safety of favipiravir, an oral RNA-  
334 dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized,  
335 comparative, open-label, multicenter, phase 3 clinical trial. *Int J Infect Dis.* 2021 Feb;103:62-71.
- 336 10. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat Med.* 2021  
337 Apr;27(4):601-615.
- 338 11. Eroglu E, Toprak C. Overview of favipiravir and remdesivir treatment for COVID-19.  
339 *International Journal of Pharmaceutical Sciences and Research.* 2021:1950-1957.
- 340 12. Kumari P, Rawat K, Saha L. Pipeline Pharmacological Therapies in Clinical Trial for  
341 COVID-19 Pandemic: a Recent Update. *Curr Pharmacol Rep.* 2020;6(5):228-240.
- 342 13. Manabe T, Kambayashi D, Akatsu H, et al. Favipiravir for the treatment of patients with  
343 COVID-19: a systematic review and meta-analysis. *BMC Infect Dis.* 2021 May 27;21(1):489.
- 344 14. Wei FF, Moradkhani A, Hezaveh HH, et al. Evaluating the Treatment with Favipiravir in  
345 Patients Infected by COVID-19: A Systematic Review and Meta-analysis *International Journal of*  
346 *Scientific Research in Dental and Medical Sciences.* 2020;2(3):87-91.
- 347 15. Kelleni MT. Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for  
348 COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment. *SN Compr Clin Med.*  
349 2021;3(4):919-923.
- 350 16. Ko M, Jeon S, Ryu WS, et al. Comparative analysis of antiviral efficacy of FDA-approved  
351 drugs against SARS-CoV-2 in human lung cells. *J Med Virol.* 2021 Mar;93(3):1403-1408.
- 352 17. Sreekanth Reddy O, Lai WF. Tackling COVID-19 Using Remdesivir and Favipiravir as  
353 Therapeutic Options. *Chembiochem.* 2021 Mar 16;22(6):939-948.

- 354 18. Shrestha DB, Budhathoki P, Khadka S, et al. Favipiravir versus other antiviral or standard  
355 of care for COVID-19 treatment: a rapid systematic review and meta-analysis. *Virology*. 2020 Sep  
356 24;17(1):141.
- 357 19. Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to Prevent Progression to Severe  
358 Covid-19 in Outpatients. *N Engl J Med*. 2022 Jan 27;386(4):305-315.
- 359 20. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment  
360 of Covid-19 in nonhospitalized patients. *New England Journal of Medicine*. 2022;386(6):509-520.
- 361 21. Thorlund K, Sheldrick K, Mills E. Molnupiravir for Covid-19 in Nonhospitalized Patients.  
362 *New England Journal of Medicine*. 2022;386(13):e32.
- 363 22. Brophy JM. Molnupiravir's authorisation was premature. *British Medical Journal*  
364 Publishing Group; 2022.
- 365 23. Seneviratne SL, Abeysuriya V, De Mel S, et al. Favipiravir in COVID-19. *International*  
366 *Journal of Progressive Sciences and Technologies*. 2020;19(2):143-145.
- 367 24. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral  
368 RNA polymerase. *Proc Jpn Acad Ser B Phys Biol Sci*. 2017;93(7):449-463.
- 369 25. Agrawal U, Raju R, Udhwadia ZF. Favipiravir: A new and emerging antiviral option in  
370 COVID-19. *Med J Armed Forces India*. 2020 Oct;76(4):370-376.
- 371 26. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently  
372 emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res*. 2020 Mar;30(3):269-271.
- 373 27. Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for Treatment of  
374 Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III  
375 Multicenter Randomized Clinical Trial. *Clin Infect Dis*. 2021 Aug 2;73(3):531-534.

- 376 28. Yanai H. Favipiravir: A Possible Pharmaceutical Treatment for COVID-19. *Journal of*  
377 *Endocrinology & Metabolism*. 2020;10(2):33-34.
- 378 29. Holubar M, Subramanian A, Purington N, et al. Favipiravir for treatment of outpatients  
379 with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled,  
380 phase 2 trial. *Clin Infect Dis*. 2022 Apr 21.
- 381 30. Shinada K, Sato T, Moriyama S, et al. Longitudinal Analysis of Neutralizing Potency  
382 against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir.  
383 *Viruses*. 2022 Mar 24;14(4).
- 384 31. Özlüşen B, Kozan Ş, Akcan RE, et al. Effectiveness of favipiravir in COVID-19: a live  
385 systematic review. *Eur J Clin Microbiol Infect Dis*. 2021 Dec;40(12):2575-2583.
- 386 32. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic  
387 review and network meta-analysis. *Bmj*. 2020 Jul 30;370:m2980.
- 388 33. Hassanipour S, Arab-Zozani M, Amani B, et al. The efficacy and safety of Favipiravir in  
389 treatment of COVID-19: a systematic review and meta-analysis of clinical trials. *Sci Rep*. 2021  
390 May 26;11(1):11022.
- 391 34. Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir - a potential  
392 treatment in the COVID-19 pandemic? *J Virus Erad*. 2020 Apr 30;6(2):45-51.
- 393 35. FUJIFILM Toyama Chemical Co. L. *Notice of The New Drug Application Approval of*  
394 *“AVIGAN® Tablet 200mg” in Japan for the Anti-influenza Virus Drug 2014*. Available from:  
395 [https://www.cdc.gov.tw/File/Get/ht8jUiB\\_MI-aKnlwstzwvw](https://www.cdc.gov.tw/File/Get/ht8jUiB_MI-aKnlwstzwvw)
- 396 36. Prasithsirikul W, Pongpirul K, Sakornsakolpat P, et al. Adjunctive favipiravir for severe  
397 COVID-19: a retrospective observational study of the first 41 patients in Thailand. *Asian*  
398 *Biomedicine*. 2020;14(3).

- 399 37. Mendenhall M, Russell A, Smee DF, et al. Effective oral favipiravir (T-705) therapy  
400 initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever. *PLoS Negl*  
401 *Trop Dis*. 2011 Oct;5(10):e1342.
- 402 38. Oestereich L, Lüdtke A, Wurr S, et al. Successful treatment of advanced Ebola virus  
403 infection with T-705 (favipiravir) in a small animal model. *Antiviral Res*. 2014 May;105:17-21.
- 404 39. Gowen BB, Wong MH, Jung KH, et al. In vitro and in vivo activities of T-705 against  
405 arenavirus and bunyavirus infections. *Antimicrob Agents Chemother*. 2007 Sep;51(9):3168-76.
- 406 40. Bai CQ, Mu JS, Kargbo D, et al. Clinical and Virological Characteristics of Ebola Virus  
407 Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014. *Clin Infect Dis*. 2016 Nov  
408 15;63(10):1288-1294.
- 409 41. Lu CC, Chen MY, Lee WS, et al. Potential therapeutic agents against COVID-19: What  
410 we know so far. *J Chin Med Assoc*. 2020 Jun;83(6):534-536.
- 411 42. Baranovich T, Wong SS, Armstrong J, et al. T-705 (favipiravir) induces lethal mutagenesis  
412 in influenza A H1N1 viruses in vitro. *J Virol*. 2013 Apr;87(7):3741-51.
- 413 43. Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad-spectrum antiviral  
414 inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.  
415 *Sci Transl Med*. 2020 Apr 29;12(541).
- 416 44. Sawanpanyalert N, Sirijatuphat R, Sangsayunh P, et al. Assessment of outcomes  
417 following implementation of antiviral treatment guidelines for COVID-19 during the first wave in  
418 Thailand. *Southeast Asian Journal of Tropical Medicine and Public Health*. 2021;52(4):572-585.
- 419 45. Fujii S, Ibe Y, Ishigo T, et al. Early favipiravir treatment was associated with early  
420 defervescence in non-severe COVID-19 patients. *Journal of Infection and Chemotherapy*.  
421 2021;27(7):1051-1057.

- 422 46. Ghasemnejad-Berenji M, Pashapour S. Favipiravir and COVID-19: A Simplified  
423 Summary. *Drug Res (Stuttg)*. 2021 Mar;71(3):166-170.
- 424 47. Srinivas P, Sacha G, Koval C. Antivirals for COVID-19. *Cleveland Clinical Journal of*  
425 *Medicine*. 2020.
- 426 48. Medical Research Foundation T. Thai Clinical Trials Registry 2021. Available from:  
427 <https://thaiclinicaltrials.org/>
- 428 49. Health Do. National Early Warning Score: National Clinical Guideline No. 1 2013.
- 429 50. Prakash A, Singh H, Kaur H, et al. Systematic review and meta-analysis of effectiveness  
430 and safety of favipiravir in the management of novel coronavirus (COVID-19) patients. *Indian J*  
431 *Pharmacol*. 2020 Sep-Oct;52(5):414-421.
- 432 51. Manosuthi W, Jeungsmarn S, Okada P, et al. Nasopharyngeal SARS-CoV-2 Viral Load  
433 Response among COVID-19 Patients Receiving Favipiravir. *Jpn J Infect Dis*. 2021 Sep  
434 22;74(5):416-420.
- 435 52. Deng W, Yang C, Yang S, et al. Evaluation of favipiravir in the treatment of COVID-19  
436 based on the real-world. *Expert Rev Anti Infect Ther*. 2022 Apr;20(4):555-565.
- 437 53. Fischer WA, 2nd, Eron JJ, Jr., Holman W, et al. A phase 2a clinical trial of molnupiravir  
438 in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of  
439 infectious virus. *Sci Transl Med*. 2022 Jan 19;14(628):eab17430.
- 440 54. Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus  
441 standard of care alone for the treatment of patients admitted to hospital with COVID-19  
442 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. *Lancet Infect Dis*. 2022  
443 Feb;22(2):209-221.

444 55. Chuah CH, Chow TS, Hor CP, et al. Efficacy of Early Treatment with Favipiravir on  
445 Disease Progression among High Risk COVID-19 Patients: A Randomized, Open-Label Clinical  
446 Trial. Clin Infect Dis. 2021 Nov 19.

447 56. 35 generic manufacturers sign agreements with MPP to produce low-cost, generic versions  
448 of Pfizer's oral COVID-19 treatment nirmatrelvir in combination with ritonavir for supply in 95  
449 low- and middle-income countries [Internet]. Medicines Patent Pool; 2022. Available from:  
450 [https://medicinespatentpool.org/news-publications-post/35-generic-manufacturers-sign-](https://medicinespatentpool.org/news-publications-post/35-generic-manufacturers-sign-agreements-with-mpp-to-produce-low-cost-generic-versions-of-pfizers-oral-covid-19-treatment-nirmatrelvir-in-combination-with-ritonavir-for-supply-in-95-low-and)  
451 [agreements-with-mpp-to-produce-low-cost-generic-versions-of-pfizers-oral-covid-19-treatment-](https://medicinespatentpool.org/news-publications-post/35-generic-manufacturers-sign-agreements-with-mpp-to-produce-low-cost-generic-versions-of-pfizers-oral-covid-19-treatment-nirmatrelvir-in-combination-with-ritonavir-for-supply-in-95-low-and)  
452 [nirmatrelvir-in-combination-with-ritonavir-for-supply-in-95-low-and](https://medicinespatentpool.org/news-publications-post/35-generic-manufacturers-sign-agreements-with-mpp-to-produce-low-cost-generic-versions-of-pfizers-oral-covid-19-treatment-nirmatrelvir-in-combination-with-ritonavir-for-supply-in-95-low-and)

453 57. 27 generic manufacturers sign agreements with MPP to produce low-cost versions of  
454 COVID-19 antiviral medication molnupiravir for supply in 105 low- and-middle-income countries  
455 [Internet]. Medicines Patent Pool; 2022. Available from: [https://medicinespatentpool.org/news-](https://medicinespatentpool.org/news-publications-post/27-generic-manufacturers-sign-agreements-with-mpp-to-produce-molnupiravir)  
456 [publications-post/27-generic-manufacturers-sign-agreements-with-mpp-to-produce-molnupiravir](https://medicinespatentpool.org/news-publications-post/27-generic-manufacturers-sign-agreements-with-mpp-to-produce-molnupiravir)

457 58. Pertinez H, Rajoli RKR, Khoo SH, et al. Pharmacokinetic modelling to estimate  
458 intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-  
459 CoV-2. J Antimicrob Chemother. 2021 Jul 15;76(8):2121-2128.

460

461 Table 1. Baseline characteristics and clinical symptoms of patients with SARS-CoV-2 infection.

Variables	Favipiravir (n=62)	Control (n=31)	p-value
<b>Baseline characteristics</b>			
Site; n (%)			
Bamrasnaradura Infectious Diseases Institute	51 (82.3)	26 (83.9)	1.000
Golden Jubilee Medical Centre	9 (14.5)	4 (12.9)	
Siriraj Hospital	2 (3.2)	1 (3.2)	
Age; Median (IQR)	32 (27-39)	28 (25-35)	0.044
Gender; n (%)			
Male	21 (33.9)	12 (38.7)	0.646
Female	41 (66.1)	19 (61.3)	
<b>Baseline clinical symptoms</b>			
Coughing			
	(n=61)	(n=30)	
None	14 (23.0)	10 (33.3)	0.156
Mild	41 (67.2)	20 (66.7)	
Moderate	6 (9.8)	-	
Sore throat			
	(n=61)	(n=30)	
None	22 (36.1)	16 (53.3)	0.178
Mild	35 (57.4)	14 (46.7)	
Moderate	4 (6.6)	-	
Headache			
	(n=61)	(n=30)	
None	46 (75.4)	24 (80.0)	0.862

<b>Variables</b>	<b>Favipiravir (n=62)</b>	<b>Control (n=31)</b>	<b>p-value</b>
Mild	14 (23.0)	6 (20.0)	
Moderate	1 (1.6)	-	
<b>Muscle or joint pain</b>	<b>(n=61)</b>	<b>(n=30)</b>	
None	48 (78.7)	24 (80.0)	1.000
Mild	12 (19.7)	6 (20.0)	
Moderate	1 (1.6)	-	
<b>Nasal congestion or nasal discharge</b>	<b>(n=61)</b>	<b>(n=30)</b>	
None	46 (75.4)	26 (86.7)	0.478
Mild	12 (19.7)	4 (13.3)	
Moderate	3 (4.9)	-	
<b>Chills or sweating</b>	<b>(n=61)</b>	<b>(n=30)</b>	
None	59 (96.7)	30 (100.0)	1.000
Mild	2 (3.3)	-	
Moderate	-	-	
<b>Malaise or fatigue</b>	<b>(n=60)</b>	<b>(n=30)</b>	
None	49 (81.7)	28 (93.3)	0.206
Mild	11 (18.3)	2 (6.7)	
Moderate	-	-	
<b>Diarrhoea</b>	<b>(n=22)</b>	<b>(n=12)</b>	
None	17 (77.3)	9 (75.0)	1.000
N/A	5 (22.7)	3 (25.0)	

<b>Variables</b>	<b>Favipiravir (n=62)</b>	<b>Control (n=31)</b>	<b>p-value</b>
Loss of taste	(n=22)	(n=12)	
No	17 (77.3)	8 (66.7)	0.687
N/A	5 (22.7)	4 (33.3)	
Loss of smell	(n=22)	(n=12)	
No	13 (59.1)	8 (66.7)	0.881
Yes	4 (18.2)	1 (8.3)	
N/A	5 (22.7)	3 (25.0)	
Fever			
No	44 (71.0)	28 (90.0)	0.035
Yes	18 (29.0)	3 (10.0)	
<b>Health conditions</b>			
Body Mass Index (BMI: kg/m <sup>2</sup> ); Median (IQR)	22 (19-25)	22 (19-26)	0.8624
Underweight (< 18.5 kg/m <sup>2</sup> )	15 (24.2)	7 (22.6)	
Normal weight (18.5 - 24.9 kg/m <sup>2</sup> )	30 (48.4)	15 (48.4)	
Overweight and obesity (> 24.9 kg/m <sup>2</sup> )	17 (27.4)	9 (29.0)	
Have underlying health conditions			
Yes	6 (9.7)	2 (6.5)	0.601
No	56 (90.3)	29 (93.5)	
SARS-CoV-2 genotypes			
Ancestral strain with D614G	15 (26.8)	5 (17.3)	0.580
B.1.1.7 (Alpha)	37 (66.1)	21 (72.4)	

<b>Variables</b>	<b>Favipiravir (n=62)</b>	<b>Control (n=31)</b>	<b>p-value</b>
B.1.617.2 (Delta)	4 (7.1)	3 (10.3)	
<b>Duration of symptoms before treatment (day(s));</b>			
Mean (SE)	1.66 (2.4)	1.64 (2.1)	0.9748
Median (IQR)	0 (0-7)	0 (0-6)	
0-4 days	56 (90.3)	26 (83.9)	
> 4 days	6 (9.7)	5 (16.1)	
<b>NEWS Score</b>			
0	24 (38.7)	10 (32.2)	0.648
1	24 (38.7)	16 (51.6)	
2	10 (16.1)	3 (9.7)	
3	4 (6.5)	2 (6.5)	

463 Table 2. Logistic regression analysis of associated factors with improvement of clinical conditions  
 464 by NEWS within 14 days in patients.

Parameter	Favipiravir (n = 62)		Control (n = 31)		All (n = 93)	
	Adjusted Odd ratio (Robust standard errors)	P-value	Adjusted Odd ratio (Robust standard errors)	P-value	Adjusted Odd ratio (Robust standard errors)	P-value
<b>Treatment</b>						
Non-favipiravir					<i>Reference</i>	
Favipiravir					9.92 (5.62)	< 0.001
Age ( <i>continuous</i> )	0.95 (0.04)	0.1614	0.99 (0.05)	0.992	0.98 (0.03)	0.453
<b>Gender</b>						
Male	<i>Reference</i>					
Female	6.35 (4.70)	< 0.001	0.69 (0.72)	0.723	1.90 (1.12)	0.275
<b>BMI</b>						
Normal weight	<i>Reference</i>					
Underweight	0.29 (0.27)	0.180	3.87 (4.55)	0.250	1.13 (0.90)	0.878
Overweight and obese	6.36 (8.88)	0.185	1.01 (1.62)	0.999	2.45 (1.70)	0.197
<b>Viral genotype</b>						


Parameter	Favipiravir (n = 62)		Control (n = 31)		All (n = 93)	
	Adjusted Odd ratio (Robust standard errors)	P-value	Adjusted Odd ratio (Robust standard errors)	P-value	Adjusted Odd ratio (Robust standard errors)	P-value
Ancestral strain with D614G	<i>Reference</i>					
Alpha and Delta	1.49 (1.26)	0.639	0.45 (0.51)	0.482	1.45 (0.87)	0.536
<b>Duration of symptoms before treatment</b> <i>(continuous)</i>	1.23 (0.24)	0.248	0.84 (0.21)	0.497	1.10 (1.13)	0.402
<b>Have underlying health conditions</b>						
No	<i>Reference</i>					
Yes	0.65 (0.75)	0.939	-		0.55 (0.45)	0.463
<b>Constant</b>	<b>0.64 (0.75)</b>	<b>0.706</b>	<b>0.77 (1.39)</b>	<b>0.887</b>	<b>0.42 (0.39)</b>	<b>0.353</b>

466 **Figure Captions**


467 Figure 1. Time to sustained clinical improvement by NEWS. The Kaplan-Meier curve illustrates  
468 the cumulative proportion of patients who experienced sustained clinical improvement, which is  
469 defined by a reduced NEWS or NEWS  $\leq 1$  for at least 7 days. The median time to sustained clinical  
470 improvement by NEWS was 2 days vs 14 days (range of 1-28 days) for FPV and control arms  
471 respectively (adjusted hazard ratio (aHR) 2.77, 95% CI 1.57-4.88,  $P < 0.001$ )

472  
473 Figure 2. Proportion of patients with clinical improvement by NEWS within 14 days of treatment.  
474 The bar graph illustrates the cumulative proportion of patients who experienced clinical  
475 improvement, which is defined as reduced NEWS or NEWS  $\leq 1$  during the 14-day treatment  
476 period. Patients that received FPV also had significantly higher likelihoods of clinical  
477 improvement within 14 days after enrolment (79% vs 32% respectively,  $P < 0.001$ )

478  
479 Figure 3. Quantitative SARS-CoV-2 viral loads over 0-28 days in FPV and control arms: (A)  
480 overall (B) participants with baseline viral load  $\geq 75^{\text{th}}$  percentile and (C) participants with  
481 baseline viral load  $\leq 25^{\text{th}}$  percentile.




Proportions of patient (%)



# SARS-CoV-2 viral loads

(Log<sub>10</sub> copies/ml and 95% confidence interval)


medRxiv preprint doi: <https://doi.org/10.1101/2022.06.06.22275902>; this version posted June 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



# SARS-CoV-2 viral loads

(Log<sub>10</sub> copies/ml and 95% confidence interval)

medRxiv preprint doi: <https://doi.org/10.1101/2022.06.06.22275902>; this version posted June 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



# SARS-CoV-2 viral loads

(Log<sub>10</sub> copies/ml and 95% confidence interval)

